Azafaros has raised €132 million in an oversubscribed Series B financing round. The funding will support the advancement of its lead clinical-stage asset, AZ-3102, into two Phase 3 trials for the treatment of rare lysosomal storage disorders: GM1 and GM2 gangliosidosis.
This significant milestone marks one of the largest private biotech financings in Europe so far in 2025. The round was led by Forbion Growth and included new investors such as Sofinnova Partners, as well as strategic investor Sarepta Therapeutics, alongside existing investors.
With this financing, Azafaros is poised to accelerate late-stage development of innovative therapies that target multiple neurological symptoms of rare genetic diseases, bringing new hope to patients and families affected by these devastating conditions.
Read more here
Last week, demissionary Minister of Social Affairs and Employment Eddy van Hijum paid a visit last week to the Post-COVID Expertise Center at Leiden University Medical Center...
Looking for something thoughtful to tune into this summer? Biopolis – Into the Microbiome is a new science podcast blending documentary storytelling with fiction to explore the...
Leiden Bio Science Park is taking concrete steps to increase biodiversity across its grounds, moving beyond ornamental landscaping to create habitats that support a wide range of...